Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
Zheng JQ, Hou YC, Zheng CM, Lu CL, Liu WC, Wu CC, Huang MT, Lin YF, Lu KC
Nutrients · 20 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Taipei Medical University
- University or hospital
- Shuang-Ho hospital, Taipei Medical University
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2016-11-05 · Nutrients · vol. 8 · issue 11 · p. 708
- Publisher
- Multidisciplinary Digital Publishing Institute
- Cited
- 25 citations · more than 87% of similar papers · 2.1× the field average
- References
- 52 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Parathyroid Disorders and Treatments · Vitamin D Research Studies · Dialysis and Renal Disease Management
- Keywords
- Paricalcitol, Parathyroid hormone, Secondary hyperparathyroidism, Cholecalciferol, Medicine, Vitamin D and neurology, Endocrinology, Internal medicine, Hyperparathyroidism, Hemodialysis, Urology, Calcium
- MeSH
- humans, kidney failure, chronic, hyperparathyroidism, secondary, cholecalciferol, calcifediol, ergocalciferols, parathyroid hormone, vitamin d, antimicrobial cationic peptides, placebos, treatment outcome, drug therapy, combination, renal dialysis, drug interactions, aged, middle aged, female, male, cathelicidins
9 authors
From TW
- Jing-Quan ZhengTaipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Yi‐Chou HouFu Jen Catholic University; Cardinal Tien Hospital
- Cai‐Mei ZhengTaipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Chien‐Lin LuTaipei Medical University
- Wen-Chih LiuFu Jen Catholic University; Cardinal Tien Hospital; Taipei Medical University
- Chia‐Chao WuTri-Service General Hospital; National Defense Medical Center
Abstract
Background
Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia. This study evaluates the possible beneficial effects of combined vitamin D treatment (paricalcitol and cholecalciferol).
Methods
Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled. All patients administered 2 mcg/day of paricalcitol and were randomly allocated into control group (placebo) or study group (cholecalciferol) for 16 weeks. Serum 25(OH)D₃, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up.
Results
iPTH levels decreased in the study group appropriately and were more significantly decreased at 16 weeks. Study group had significantly increased 25(OH)D₃ levels. In addition, the study group had significantly increased serum hCAP-18 levels compared with control group. Correlation analysis showed a significant correlation between the percentage increase in serum hCAP-18 and 25(OH)D₃ levels.
Conclusions
Cholecalciferol, in combination with paricalcitol, additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation. A dose of 5000 IU/week of cholecalciferol could maintain serum 25(OH)D₃ levels above 30 ng/dL as early as 8 weeks after beginning supplementation. Doubling of serum cathelicidin levels were noted after 16 weeks of cholecalciferol supplementation in 40% of study patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.